We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$589M
AUM Growth
+$77.1M
Cap. Flow
+$17.1M
Cap. Flow %
2.91%
Top 10 Hldgs %
37.04%
Holding
153
New
41
Increased
30
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.2M
2
GILD icon
Gilead Sciences
GILD
+$15.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
TSRO
TESARO, Inc.
TSRO
+$7.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.09M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.32M
4
NVS icon
Novartis
NVS
+$4.35M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 66.11%
2 Technology 6.31%
3 Industrials 2.63%
4 Communication Services 2.28%
5 Financials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
26
Kyntra Bio
KYNB
$27.2M
$5.35M 0.91%
6,628
– –
CLLS
27
Cellectis
CLLS
$277M
$5.26M 0.89%
203,764
+44,100
+28% +$1.05M
V icon
28
Visa
V
$684B
$4.97M 0.84%
52,951
– –
AVEO
29
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.88M 0.83%
220,000
-70,000
-24% -$551K
META icon
30
Meta Platforms (Facebook)
META
$1.42T
$4.86M 0.83%
32,167
+14,075
+78% +$2.09M
IMMU
31
DELISTED
Immunomedics Inc
IMMU
$4.86M 0.83%
550,000
-400,000
-42% -$2.81M
UNP icon
32
Union Pacific
UNP
$174B
$4.62M 0.78%
42,400
+13,730
+48% +$1.5M
RNAC icon
33
Cartesian Therapeutics
RNAC
$229M
$4.54M 0.77%
7,618
– –
CHTR icon
34
Charter Communications
CHTR
$17.3B
$4.5M 0.76%
13,362
+1,402
+12% +$468K
ASND icon
35
Ascendis Pharma A/S
ASND
$16B
$4.49M 0.76%
161,617
-93,838
-37% -$2.48M
CSTE icon
36
Caesarstone
CSTE
$72.3M
$4.3M 0.73%
122,797
+32,823
+36% +$1.23M
NERV icon
37
Minerva Neurosciences
NERV
$185M
$4.19M 0.71%
+59,221
New +$3.83M
RXDX
38
DELISTED
Ignyta, Inc.
RXDX
$4.14M 0.7%
+400,000
New +$3.25M
SNDX icon
39
Syndax Pharmaceuticals
SNDX
$1.69B
$4.14M 0.7%
296,310
+130,000
+78% +$1.49M
ALDX icon
40
Aldeyra Therapeutics
ALDX
$92.9M
$4.12M 0.7%
875,931
+207,431
+31% +$954K
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.1M 0.7%
+150,000
New +$4.46M
TVTX icon
42
Travere Therapeutics
TVTX
$5.2B
$4.05M 0.69%
209,131
– –
GOOGL icon
43
Alphabet (Google) Class A
GOOGL
$4.36T
$4.04M 0.69%
86,920
– –
FOLD
44
DELISTED
Amicus Therapeutics
FOLD
$4.03M 0.68%
400,000
-100,000
-20% -$805K
ALNY icon
45
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.99M 0.68%
+50,000
New +$3.2M
NOMD icon
46
Nomad Foods
NOMD
$1.66B
$3.78M 0.64%
+268,072
New +$3.43M
LJPC
47
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.72M 0.63%
125,000
+15,000
+14% +$430K
ICPT
48
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.63M 0.62%
30,000
+15,000
+100% +$1.74M
TEVA icon
49
PUT
Teva Pharmaceuticals
TEVA
$40.8B
$3.6M 0.61%
+1,120
New +$34.7K
CBIO
50
Crescent Biopharma
CBIO
$537M
$3.58M 0.61%
3,208
-4,550
-59% -$3.76M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sphera Funds Management held 153 positions worth $589M, up 15% from $512M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management's Q2 2017 filing shows 41 new, 30 increased, 20 reduced and 25 closed positions. Its largest new stake was GSK: 360,000 shares worth $19.4M. The largest sale was Shire pic, an estimated $25.5M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q2 2017 buy was GSK: 360,000 shares worth $19.4M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $5.33M increase.
  • Sphera Funds Management's biggest Q2 2017 reduction was Shire pic, cutting an estimated $25.5M.
  • Sphera Funds Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $7.09M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $589M portfolio in Q2 2017.
  • Sphera Funds Management opened 41 new positions and closed 25 in Q2 2017.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $589M.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.